Posted by Michael Wonder on 27 Sep 2023
Ocuphire Pharma and Viatris announce FDA approval of Ryzumvi (phentolamine ophthalmic solution) 0.75% eye drops for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents
27 September 2023 - Ryzumvi expected to be commercially available in the US in the first half of 2024.
Ocuphire Pharma and Viatris today announced that the US FDA has approved Ryzumvi (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents.
